Division of Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, Padua 35128, Italy.
Division of Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, Padua 35128, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, via Giustiniani 2, Padova 35128, Italy.
Crit Rev Oncol Hematol. 2024 Nov;203:104479. doi: 10.1016/j.critrevonc.2024.104479. Epub 2024 Aug 14.
Radiomics, analysing quantitative features from medical imaging, has rapidly become an emerging field in translational oncology. Radiomics has been investigated in several neoplastic malignancies as it might allow for a non-invasive tumour characterization and for the identification of predictive and prognostic biomarkers. Over the last few years, evidence has been accumulating regarding potential clinical applications of machine learning in many crucial moments of cancer patients' history. However, the incorporation of radiomics in clinical decision-making process is still limited by low data reproducibility and study variability. Moreover, the need for prospective validations and standardizations is emerging. In this narrative review, we summarize current evidence regarding radiomic applications in high-incidence cancers (breast and lung) for screening, diagnosis, staging, treatment choice, response, and clinical outcome evaluation. We also discuss pro and cons of the radiomic approach, suggesting possible solutions to critical issues which might invalidate radiomics studies and propose future perspectives.
放射组学,即从医学影像中分析定量特征,已迅速成为转化肿瘤学领域的一个新兴领域。放射组学已经在多种肿瘤恶性肿瘤中进行了研究,因为它可能允许对肿瘤进行非侵入性特征描述,并识别预测和预后生物标志物。在过去的几年中,关于机器学习在癌症患者病史的许多关键时刻的潜在临床应用的证据不断增加。然而,放射组学在临床决策过程中的应用仍然受到数据可重复性和研究变异性低的限制。此外,还需要进行前瞻性验证和标准化。在这篇叙述性综述中,我们总结了目前关于放射组学在高发癌症(乳腺和肺癌)中的应用的证据,用于筛查、诊断、分期、治疗选择、反应和临床结果评估。我们还讨论了放射组学方法的优缺点,提出了可能解决可能使放射组学研究无效的关键问题的解决方案,并提出了未来的展望。